Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

Consolidated Research: 2019 Summary Expectations for Wyndham Hotels & Resorts, Apellis Pharmaceuticals, Transcat, Emerald Expositions Events, Capitala Finance, and Seres Therapeutics — Fundamental Analysis, Key Performance Indications

Share:

NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Wyndham Hotels & Resorts Inc. (NYSE:WH), Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Transcat, Inc. (NASDAQ:TRNS), Emerald Expositions Events, Inc. (NYSE:EEX), Capitala Finance Corp. (NASDAQ:CPTA), and Seres Therapeutics, Inc. (NASDAQ:MCRB), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

WH DOWNLOAD: http://Capital-Review.com/register/?so=WH
APLS DOWNLOAD: http://Capital-Review.com/register/?so=APLS
TRNS DOWNLOAD: http://Capital-Review.com/register/?so=TRNS
EEX DOWNLOAD: http://Capital-Review.com/register/?so=EEX
CPTA DOWNLOAD: http://Capital-Review.com/register/?so=CPTA
MCRB DOWNLOAD: http://Capital-Review.com/register/?so=MCRB

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Wyndham Hotels & Resorts Inc. (NYSE:WH), Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Transcat, Inc. (NASDAQ:TRNS), Emerald Expositions Events, Inc. (NYSE:EEX), Capitala Finance Corp. (NASDAQ:CPTA), and Seres Therapeutics, Inc. (NASDAQ:MCRB) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

WYNDHAM HOTELS & RESORTS INC. (WH) REPORT OVERVIEW

Wyndham Hotels & Resorts' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Wyndham Hotels & Resorts reported revenue of $527.00MM vs $313.00MM (up 68.37%) and analysts estimated basic earnings per share $0.83 vs $1.25 (down 33.60%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Wyndham Hotels & Resorts reported revenue of $1,868.00MM vs $1,280.00MM (up 45.94%) and analysts estimated basic earnings per share $1.62 vs $2.31 (down 29.87%). Analysts expect earnings to be released on April 30th, 2019. The report will be for the fiscal period ending March 31st, 2019. The estimated EPS forecast for the next fiscal year is $3.60 and is expected to report on February 12th, 2020.

To read the full Wyndham Hotels & Resorts Inc. (WH) report, download it here: http://Capital-Review.com/register/?so=WH

-----------------------------------------

APELLIS PHARMACEUTICALS, INC. (APLS) REPORT OVERVIEW

Apellis Pharmaceuticals' Recent Financial Performance

Analysts expect earnings to be released on April 29th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.43. The estimated EPS forecast for the next fiscal year is -$3.31 and is expected to report on February 25th, 2020.

To read the full Apellis Pharmaceuticals, Inc. (APLS) report, download it here: http://Capital-Review.com/register/?so=APLS

-----------------------------------------

TRANSCAT, INC. (TRNS) REPORT OVERVIEW

Transcat's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Transcat reported revenue of $40.87MM vs $40.48MM (up 0.95%) and analysts estimated basic earnings per share $0.22 vs $0.26 (down 15.38%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, Transcat reported revenue of $155.14MM vs $143.90MM (up 7.81%) and analysts estimated basic earnings per share $0.83 vs $0.65 (up 27.69%). Analysts expect earnings to be released on May 28th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.27. The estimated EPS forecast for the next fiscal year is $1.01 and is expected to report on May 28th, 2019.

To read the full Transcat, Inc. (TRNS) report, download it here: http://Capital-Review.com/register/?so=TRNS

-----------------------------------------

EMERALD EXPOSITIONS EVENTS, INC. (EEX) REPORT OVERVIEW

Emerald Expositions Events' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Emerald Expositions Events reported revenue of $57.00MM vs $31.50MM (up 80.95%) and basic earnings per share -$1.23 vs $0.55. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Emerald Expositions Events reported revenue of $380.70MM vs $341.70MM (up 11.41%) and analysts estimated basic earnings per share -$0.34 vs $1.19. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.66. The estimated EPS forecast for the next fiscal year is $1.16 and is expected to report on February 13th, 2020.

To read the full Emerald Expositions Events, Inc. (EEX) report, download it here: http://Capital-Review.com/register/?so=EEX

-----------------------------------------

CAPITALA FINANCE CORP. (CPTA) REPORT OVERVIEW

Capitala Finance's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Capitala Finance reported revenue of $15.66MM vs $18.74MM (down 16.46%) and analysts estimated basic earnings per share -$0.58 vs -$0.04. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Capitala Finance reported revenue of $51.64MM vs $58.23MM (down 11.32%) and analysts estimated basic earnings per share -$1.00 vs -$0.44. Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.28. The estimated EPS forecast for the next fiscal year is $1.00 and is expected to report on March 2nd, 2020.

To read the full Capitala Finance Corp. (CPTA) report, download it here: http://Capital-Review.com/register/?so=CPTA

-----------------------------------------

SERES THERAPEUTICS, INC. (MCRB) REPORT OVERVIEW

Seres Therapeutics' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Seres Therapeutics reported revenue of $10.63MM vs $3.06MM (up 247.81%) and analysts estimated basic earnings per share -$0.52 vs -$0.72. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Seres Therapeutics reported revenue of $28.27MM vs $32.10MM (down 11.94%) and analysts estimated basic earnings per share -$2.43 vs -$2.21. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.69. The estimated EPS forecast for the next fiscal year is -$2.10 and is expected to report on March 4th, 2020.

To read the full Seres Therapeutics, Inc. (MCRB) report, download it here: http://Capital-Review.com/register/?so=MCRB

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

View Comments and Join the Discussion!
 

Latest Ratings

StockFirmActionPT
BSXMaintains45.0
CLMaintains68.0
HPMaintains75.0
KMBMaintains145.0
AMNMaintains60.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com